secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K/A
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001193125-25-278466
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Therapeutics Q3 2025 net loss $20.1M; completed Phase 1b enrollment for ELVN-001 in CML
--------------------------------------------------------------------------------

- Completed enrollment of randomized Phase 1b cohorts of ENABLE trial of ELVN-001 in CML; on track for Phase 3 pivotal trial in 2026.
- Cash, equivalents and marketable securities of $477.6M at Sep 30, 2025, expected to fund operations into first half 2029.
- Net loss of $20.1M for Q3 2025 vs $23.2M in Q3 2024; R&D expenses $18.2M, G&A $6.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312525278466/0001193125-25-278466-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312525278466/elvn-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-278466

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer